Plasma metagenomic cell-free DNA sequencing identifies clinically unsuspected cases of Toxoplasma gondii infection in immunocompromised patients: a single-centre experience
6 affiliations
- 1University of Minnesota Medical School, Minneapolis, USA
- 2Division of Pediatric Infectious Diseases, University of Minnesota Medical School, Minneapolis, USA
- 3Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, USA
- 4Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, USA
- 5Division of Stem Cell Transplantation and Children’s Research Center and Pediatric Hematology and Oncology University Children’s Hospital Zurich, University of Zürich, Zürich, Switzerland
- 6Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kantonsspital Aarau, Aarau, Switzerland
Abstract
Toxoplasmosis can be challenging to diagnose, particularly in immunocompromised patients with nonspecific clinical presentations. We present a retrospective, single-centre case series of eight Toxoplasma gondii infections identified by plasma metagenomic cell-free DNA (cfDNA) sequencing in allogeneic haematopoietic stem cell transplant recipients. Nested within a larger cohort evaluating cfDNA utilization, this case series highlights a positive clinical impact of cfDNA testing in 5 out of 8 (62.5%) patients, including earlier diagnosis and changes in clinical management. These findings illustrate the potential utility of plasma cfDNA sequencing as a complement to conventional diagnostics across diverse clinical presentations of toxoplasmosis.
Related
- Analysis of structural modifications and metagenomic sequencing during the ensiling of Caragana korshinskii provides insights into how extrusion pretreatment promotes lignocellulose degradation
- Benchmarking Microbiome Methods for Improved Metagenomic Sequencing of Lower Respiratory Tract Samples
- Cerebrospinal fluid metagenomic next-generation sequencing for culture-negative anaerobic central nervous system infection involving Prevotella oris: attribution challenges in low-biomass specimens
- Geomosaic: a flexible bioinformatics platform integrating complementary metagenomic analyses from sequencing reads to genomes
- Metagenomic next-generation sequencing of aqueous humor guides targeted therapy for Staphylococcus epidermidis endophthalmitis in chronic ocular graft-versus-host disease: a case report
BibTeX
@article{goren2026plasma,
title = {{Plasma metagenomic cell-free DNA sequencing identifies clinically unsuspected cases of Toxoplasma gondii infection in immunocompromised patients: a single-centre experience}},
author = {Lea R. Goren and Alice C. Lehman and Daniel Drozdov and Beth Kristine Thielen},
journal = {Access Microbiology},
year = {2026},
month = nov,
doi = {10.1099/acmi.0.001068.v4},
url = {https://doi.org/10.1099/acmi.0.001068.v4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Plasma metagenomic cell-free DNA sequencing identifies clinically unsuspected cases of Toxoplasma gondii infection in immunocompromised patients: a single-centre experience
AU - Lea R. Goren
AU - Alice C. Lehman
AU - Daniel Drozdov
AU - Beth Kristine Thielen
PY - 2026
DA - 2026/11/12
JO - Access Microbiology
DO - 10.1099/acmi.0.001068.v4
UR - https://doi.org/10.1099/acmi.0.001068.v4
AB - Toxoplasmosis can be challenging to diagnose, particularly in immunocompromised patients with nonspecific clinical presentations. We present a retrospective, single-centre case series of eight Toxoplasma gondii infections identified by plasma metagenomic cell-free DNA (cfDNA) sequencing in allogeneic haematopoietic stem cell transplant recipients. Nested within a larger cohort evaluating cfDNA utilization, this case series highlights a positive clinical impact of cfDNA testing in 5 out of 8 (62.5%) patients, including earlier diagnosis and changes in clinical management. These findings illustrate the potential utility of plasma cfDNA sequencing as a complement to conventional diagnostics across diverse clinical presentations of toxoplasmosis.
SN - 2516-8290
ER -